Q2 2024 Earnings Forecast for Panbela Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:PBLA)

Panbela Therapeutics, Inc. (NASDAQ:PBLAFree Report) – Equities research analysts at HC Wainwright dropped their Q2 2024 EPS estimates for Panbela Therapeutics in a report issued on Thursday, May 16th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($2.07) per share for the quarter, down from their prior forecast of ($1.28). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Panbela Therapeutics’ current full-year earnings is ($8.38) per share. HC Wainwright also issued estimates for Panbela Therapeutics’ Q3 2024 earnings at ($2.07) EPS, Q4 2024 earnings at ($1.98) EPS, FY2024 earnings at ($8.38) EPS, FY2025 earnings at ($3.75) EPS, FY2026 earnings at ($2.78) EPS and FY2027 earnings at ($1.01) EPS.

Panbela Therapeutics (NASDAQ:PBLAGet Free Report) last posted its quarterly earnings data on Tuesday, March 26th. The company reported ($65.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($24.34) by ($41.56).

Separately, Roth Mkm reaffirmed a “buy” rating on shares of Panbela Therapeutics in a research report on Wednesday, March 27th.

View Our Latest Report on PBLA

Panbela Therapeutics Stock Performance

Panbela Therapeutics stock opened at $0.43 on Monday. The stock has a market cap of $1.48 million, a PE ratio of 0.00 and a beta of 1.55. The stock has a 50-day moving average of $0.51 and a two-hundred day moving average of $5.71. Panbela Therapeutics has a one year low of $0.35 and a one year high of $240.00.

Panbela Therapeutics Company Profile

(Get Free Report)

Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.

Read More

Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.